GLP-1/Glucagon-Like Peptide Human

Introduction to the Molecule

GLP-1 is a peptide hormone from the intestinal mucosa, which is produced from its precursor, proglucagon by post transnational processing. GLP-1 may play a role in the physiological control of feeding. GLP-1 amide was supposed to improved glycemic control in patients with type 2 diabetes by increasing insulin secretion, by inhibiting glucagon secretion and by delaying gastric emptying rather than by altering extrapancreatic glucose metabolism. Intravenous GLP-1 and amide could normalize fasting hyperglycaemia in type 2 diabetic patients. Hyperglycaemia during parenteral nutrition could be controlled by exogenous GLP-1, whereas the chronic therapy of type 2 diabetes required GLP-1 derivatives with longer duration of action.

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation

Description

Total 37 AA. MW: 4169.5 Da (Mass Spectral Analysis)

Amino Acid Sequence

Purity

97.8% (RP-HPLC)

Formulation

Lyophilized

Reconstitution

Add deionized water to prepare a working stock solution of approximately 1.0 mg/mL and let the lyophilized pellet dissolve completely. Product is not sterile! Please filter the product by an appropriate sterile filter before using it in the cell culture.

Storage, Stability/Shelf Life

Store lyophilized peptide at –20°C. Lyophilized peptide remains stable until the expiry date when stored at –20°C. Reconstituted peptide can be stored at 4°C for a limited period of time.

Quality Control Test

RP-HPLC

Note

This product is intended for research use only.

Physical Appearance

White lyophilized powder

References

• Geary N, Hrupka B, Corp ES, Asarian L. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998 Jun 1;64 (3):367-72
• Heinrich G, Gros P, Habener JF. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem. 1984 Nov 25;259 (22):14082-7
• Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 Nov-Dec;18 (6):430-41
• Holst JJ, Kofod H, Wettergren A, Rabenhoj L, Orskov C. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994 Apr;43 (4):535-9
• Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265 (14):8001-8
• Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004 Mar;91 (3):439-46
• Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15 (11):937-45
• Rizza RA, Holst JJ, Basu A, Basu R, Shah P, Vella A. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000 Apr;49 (4):611-7
• Schmidt WE, Gallwitz B, Holst JJ, Senkal M, El-Ouaghlidi A, Vethacke A, Walberg J, Nauck MA, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004 Apr 15;118 (1-2):89-97
• Tsujimoto G, Miyazaki S, Sugimoto Y, Yamada M, Adachi T, Katsuma S, Awaji T, Tsumaya K, Hirasawa A. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005 Jan;11 (1):90-4
• Yanaihara N. [Recent advances in gastrointestinal hormones]. Hum Cell. 1990 Mar;3 (1):1-8

By research topic:

• Diabetology - Other Relevant Products
• Energy metabolism and body weight regulation

By molecule:

• Glucagon-Like Peptide-1